Allakos Inc
NASDAQ:ALLK

Watchlist Manager
Allakos Inc Logo
Allakos Inc
NASDAQ:ALLK
Watchlist
Price: 1.29 USD 7.5% Market Closed
Market Cap: 115.2m USD
Have any thoughts about
Allakos Inc?
Write Note

Allakos Inc
Stock-Based Compensation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Allakos Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Allakos Inc
NASDAQ:ALLK
Stock-Based Compensation
$29.9m
CAGR 3-Years
-14%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Stock-Based Compensation
$872m
CAGR 3-Years
8%
CAGR 5-Years
16%
CAGR 10-Years
14%
Gilead Sciences Inc
NASDAQ:GILD
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Stock-Based Compensation
$739.3m
CAGR 3-Years
21%
CAGR 5-Years
16%
CAGR 10-Years
17%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Allakos Inc
Glance View

Market Cap
115.3m USD
Industry
Biotechnology

Allakos, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Redwood City, California and currently employs 192 full-time employees. The company went IPO on 2018-07-19. The firm is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. The company is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. The company also developed a formulation of lirentelimab for subcutaneous (SC) administration. The firm is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.

ALLK Intrinsic Value
1.04 USD
Overvaluation 20%
Intrinsic Value
Price

See Also

What is Allakos Inc's Stock-Based Compensation?
Stock-Based Compensation
29.9m USD

Based on the financial report for Sep 30, 2024, Allakos Inc's Stock-Based Compensation amounts to 29.9m USD.

What is Allakos Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
19%

Over the last year, the Stock-Based Compensation growth was -26%. The average annual Stock-Based Compensation growth rates for Allakos Inc have been -14% over the past three years , 19% over the past five years .

Back to Top